Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2015, Article ID 352670, 7 pages
http://dx.doi.org/10.1155/2015/352670
Review Article

The Diagnostic Accuracy of HE4 in Lung Cancer: A Meta-Analysis

Department of Transfusion, First Hospital of China Medical University, Shenyang 110001, China

Received 7 December 2014; Accepted 20 February 2015

Academic Editor: Gad Rennert

Copyright © 2015 Daye Cheng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. She, P. Yang, Q. Hong, and C. Bai, “Lung cancer in China: challenges and interventions,” Chest, vol. 143, no. 4, pp. 1117–1126, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. Q. Lan, R. S. Chapman, D. M. Schreinemachers, L. Tian, and X. He, “Household stove improvement and risk of lung cancer in Xuanwei, China,” Journal of the National Cancer Institute, vol. 94, no. 11, pp. 826–835, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Jemal, R. Siegel, J. Xu, and E. Ward, “Cancer statistics, 2010,” CA Cancer Journal for Clinicians, vol. 60, no. 5, pp. 277–300, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Jemal, R. Siegel, E. Ward et al., “Cancer statistics, 2008,” CA—Cancer Journal for Clinicians, vol. 58, no. 2, pp. 71–96, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Grunnet and J. B. Sorensen, “Carcinoembryonic antigen (CEA) as tumor marker in lung cancer,” Lung Cancer, vol. 76, no. 2, pp. 138–143, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Tufman and R. M. Huber, “Biological markers in lung cancer: a clinician's perspective,” Cancer Biomarkers, vol. 6, no. 3-4, pp. 123–135, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Kulpa, E. Wójcik, A. Radkowski, L. Kolodziejski, and Z. Stasik, “CYFRA 21-1, TPA-M, TPS, SCC-Ag and CEA in patients with squamous cell lung cancer and in chemical industry workers as a reference group,” Anticancer Research, vol. 20, no. 6, pp. 5035–5040, 2000. View at Google Scholar · View at Scopus
  8. P.-J. Lamy, J. Grenier, A. Kramar, and J.-L. Pujol, “Pro-gastrin-releasing peptide, neuron specific enolase and chromogranin A as serum markers of small cell lung cancer,” Lung Cancer, vol. 29, no. 3, pp. 197–203, 2000. View at Publisher · View at Google Scholar · View at Scopus
  9. B. Nisman, H. Biran, N. Ramu, N. Heching, V. Barak, and T. Peretz, “The diagnostic and prognostic value of ProGRP in lung cancer,” Anticancer Research, vol. 29, no. 11, pp. 4827–4832, 2009. View at Google Scholar · View at Scopus
  10. E. Wójcik, J. K. Kulpa, B. Sas-Korczyńska, S. Korzeniowski, and J. Jakubowicz, “ProGRP and NSE in therapy monitoring in patients with small cell lung cancer,” Anticancer Research, vol. 28, no. 5, pp. 3027–3033, 2008. View at Google Scholar · View at Scopus
  11. A. Clauss, H. Lilja, and Å. Lundwall, “A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acidic protein,” Biochemical Journal, vol. 368, part 1, pp. 233–242, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Kirchhoff, “Molecular characterization of epididymal proteins,” Reviews of Reproduction, vol. 3, no. 2, pp. 86–95, 1998. View at Publisher · View at Google Scholar · View at Scopus
  13. J. M. Escudero, J. M. Auge, X. Filella, A. Torne, J. Pahisa, and R. Molina, “Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases,” Clinical Chemistry, vol. 57, no. 11, pp. 1534–1544, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. S.-I. Yamashita, K. Tokuishi, T. Hashimoto et al., “Prognostic significance of HE4 expression in pulmonary adenocarcinoma,” Tumor Biology, vol. 32, no. 2, pp. 265–271, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Iwahori, H. Suzuki, Y. Kishi et al., “Serum HE4 as a diagnostic and prognostic marker for lung cancer,” Tumour Biology, vol. 33, no. 4, pp. 1141–1149, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. W. Liu, J. Yang, P. D. Chi et al., “Evaluating the clinical significance of serum HE4 levels in lung cancer and pulmonary tuberculosis,” International Journal of Tuberculosis and Lung Disease, vol. 17, no. 10, pp. 1346–1353, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. E. Y. Ucar, A. L. Ozkaya, O. Araz et al., “Serum and bronchial aspiration fluid HE-4 levels in lung cancer,” Tumor Biology, vol. 35, no. 9, pp. 8795–8799, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. X. Wang, Y. Fan, J. Wang, H. Wang, and W. Liu, “Evaluating the expression and diagnostic value of human epididymis protein 4 (HE4) in small cell lung cancer,” Tumor Biology, vol. 35, no. 7, pp. 6847–6853, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. F. Yu, Q. Wang, D. Zhong et al., “The significance of serum HE4 levels in the diagnosis of lung cancer,” Tianjin Medical Journal, vol. 42, no. 2, pp. 116–118, 2014. View at Google Scholar
  20. Y. Xiao, H. Hu, R. Wang et al., “Investigation on serum HE4 levels in the diagnosis of lung cancer,” Laboratory Medicine, vol. 29, no. 9, pp. 893–896, 2014. View at Google Scholar
  21. P. Whiting, A. W. S. Rutjes, J. B. Reitsma, P. M. M. Bossuyt, and J. Kleijnen, “The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews,” BMC Medical Research Methodology, vol. 3, article 1, pp. 1–13, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. L. E. Moses, D. Shapiro, and B. Littenberg, “Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations,” Statistics in Medicine, vol. 12, no. 14, pp. 1293–1316, 1993. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Egger, G. D. Smith, M. Schneider, and C. Minder, “Bias in meta-analysis detected by a simple, graphical test,” British Medical Journal, vol. 315, no. 7109, pp. 629–634, 1997. View at Publisher · View at Google Scholar · View at Scopus
  24. D. Yin, Y. Jiang, N. Wang et al., “The diagnostic value of serum hybrid capture 2 (CH2) HPV DNA in cervical cancer: a systematic review and meta-analysis,” Tumor Biology, vol. 35, no. 9, pp. 9247–9253, 2014. View at Publisher · View at Google Scholar
  25. A. Clauss, H. Lilja, and Å. Lundwall, “The evolution of a genetic locus encoding small serine proteinase inhibitors,” Biochemical and Biophysical Research Communications, vol. 333, no. 2, pp. 383–389, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. S.-W. Jiang, H. Chen, S. Dowdy et al., “HE4 transcription- and splice variants-specific expression in endometrial cancer and correlation with patient survival,” International Journal of Molecular Sciences, vol. 14, no. 11, pp. 22655–22677, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Kamei, S.-I. Yamashita, K. Tokuishi et al., “HE4 expression can be associated with lymph node metastases and disease-free survival in breast cancer,” Anticancer Research, vol. 30, no. 11, pp. 4779–4783, 2010. View at Google Scholar · View at Scopus
  28. R. L. O'Neal, K. T. Nam, B. J. Lafleur et al., “Human epididymis protein 4 is up-regulated in gastric and pancreatic adenocarcinomas,” Human Pathology, vol. 44, no. 5, pp. 734–742, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. Z. Xi, M. LinLin, and T. Ye, “Human epididymis protein 4 is a biomarker for transitional cell carcinoma in the urinary system,” Journal of Clinical Laboratory Analysis, vol. 23, no. 6, pp. 357–361, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. R. Drapkin, H. H. von Horsten, Y. Lin et al., “Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas,” Cancer Research, vol. 65, no. 6, pp. 2162–2169, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. A. C. Macedo, M. I. da Rosa, S. Lumertz, and L. R. Medeiros, “Accuracy of serum human epididymis protein 4 in ovarian cancer diagnosis: a systematic review and meta-analysis,” International Journal of Gynecological Cancer, vol. 24, no. 7, pp. 1222–1231, 2014. View at Publisher · View at Google Scholar
  32. E. Piovano, L. Attamante, C. Macchi et al., “The role of HE4 in ovarian cancer follow-up: a review,” International Journal of Gynecological Cancer, vol. 24, no. 8, pp. 1359–1365, 2014. View at Google Scholar
  33. X.-Y. Chu, X.-B. Hou, W.-A. Song, Z.-Q. Xue, B. Wang, and L.-B. Zhang, “Diagnostic values of SCC, CEA, Cyfra21-1 and NSE for lung cancer in patients with suspicious pulmonary masses: a single center analysis,” Cancer Biology & Therapy, vol. 11, no. 12, pp. 995–1000, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. M. R. De Sousa and A. L. P. Ribeiro, “Systematic review and meta-analysis of diagnostic and prognostic studies: a tutorial,” Arquivos Brasileiros de Cardiologia, vol. 92, no. 3, pp. 235–245, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. Z. Huang and F. Liu, “Diagnostic value of serum carbohydrate antigen 19-9 in pancreatic cancer: a meta-analysis,” Tumor Biology, vol. 35, no. 8, pp. 7459–7465, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. S. D. Walter, “Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data,” Statistics in Medicine, vol. 21, no. 9, pp. 1237–1256, 2002. View at Publisher · View at Google Scholar · View at Scopus
  37. M. D. Coory, “Comment on: heterogeneity in meta-analysis should be expected and appropriately quantified,” International Journal of Epidemiology, vol. 39, no. 3, Article ID dyp157, p. 932, 2009. View at Publisher · View at Google Scholar · View at Scopus